Yes, starting Valtrex (valacyclovir) was appropriate for this presentation
Given the clinical picture of painful fluid-filled vesicles at the corner of the mouth with facial numbness, valacyclovir was the correct initial medication choice, as this presentation is most consistent with herpes zoster (shingles) involving the trigeminal nerve rather than simple herpes labialis.
Clinical Reasoning
The key distinguishing feature here is facial numbness accompanying the vesicular eruption. This strongly suggests herpes zoster affecting the trigeminal nerve distribution rather than herpes simplex labialis (cold sores):
- Herpes labialis (HSV-1): Presents with vesicles on/around lips but does NOT cause facial numbness
- Trigeminal herpes zoster (VZV): Presents with painful vesicles in trigeminal distribution AND commonly causes facial numbness/paresthesias due to nerve involvement 1, 2
FDA-Approved Dosing
For herpes zoster, the FDA-approved valacyclovir dosing is 1 gram three times daily 3. This is substantially higher than the herpes labialis dosing (2 grams twice daily for just 1 day).
For herpes labialis (if this were the diagnosis), the dosing would be 2 grams twice daily for 1 day only 3.
Critical Timing Considerations
Treatment must be initiated within 72 hours of rash onset for optimal efficacy in herpes zoster 3. The FDA label explicitly states "there are no data on treatment initiated more than 72 hours after onset of the zoster rash" 3.
For herpes labialis, treatment should ideally begin during the prodromal stage (tingling, itching, burning) and "there are no data on the effectiveness of treatment initiated after the development of clinical signs" 3.
Dosing Adjustment Based on Age
If this patient is middle-aged or elderly (45-74 years), higher-dose valacyclovir (900 mg three times daily) significantly reduces pain and postherpetic neuralgia (PHN) incidence compared to lower doses 4. The standard 1 gram three times daily FDA-approved dose aligns with this evidence.
Common Pitfall to Avoid
Do not confuse trigeminal herpes zoster with herpes labialis. The presence of facial numbness is the critical distinguishing feature. Case reports document trigeminal herpes zoster with mucosal involvement can occur even in patients on prophylactic valacyclovir for suspected herpes labialis 1, and the condition can extend to involve adjacent nerve distributions 2.
Safety Monitoring
Watch for:
- Acute renal failure: Ensure adequate hydration; dose-adjust for renal impairment 3
- CNS effects: Confusion, hallucinations, seizures (especially in elderly or renally impaired) 3
- Severe cutaneous reactions: Stop immediately if painful rash with mucosal involvement or progressive severe rash develops 3
The medication choice was correct, but verify the dose is appropriate for herpes zoster (1 gram three times daily for 7 days) rather than herpes labialis dosing 3, 5.